AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
SAN FRANCISCO -- Tamoxifen is successful in preventing breast cancer in women with familial BRCA2 mutations but not BRCA1 mutations, Mary-Claire King, Ph.D., said during the annual meeting of the American Society of Clinical Oncology.
In a study of the women who developed breast cancer during the National Surgical Adjuvant Breast and Bowel Project, tamoxifen reduced breast cancer risk by 62% in those with a BRCA2 mutation. For women with a BRCA1 mutation, there appeared to be no risk reduction, said Dr. King, professor of medicine and genetics at the University of Washington, Seattle.
The finding is consistent with the fact that estrogen receptor-positive breast cancers are much more common among women with BRCA2 mutations than among those with BRCA1 mutations. Eighty percent of breast cancers among women with BRCA2 mutations are estrogen receptor-positive, while 80% of breast cancers among those with BRCA1 mutations are estrogen receptor-negative, Dr. King said.
The findings do not have any implication for treatment with tamoxifen, she said. Studies have shown that estrogen receptor-positive patients respond to tamoxifen chemotherapy regardless of their familial mutation.
"Our data bear on incidence, not on treatment," she said.
For her study, Dr. King took the blood samples provided at enrollment in the study of those women who developed breast cancer during the trial and examined them for possible ERCA mutations. ...
Source: HighBeam Research, Tamoxifen Effective Only With BRCA2 Mutations.